Evaluating Immune Response to Seasonal FluMist in Healthy Adults

• Status: Terminated
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The Live-Attenuated Influenza Vaccine (LAIV), also known as FluMist, has been shown to be effective in children but less effective in adults. Our hypothesis is that this relative failure is due to adults having enough anti-flu IgA antibody in nasal secretions to neutralize the weakened vaccine virus.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Center for Occupational Health and Infection Control
• Collaborators: US Department of Veterans Affairs; VA Office of Research and Development
• Treatments: Vaccines

Criteria

Inclusion Criteria:

• Medically eligible healthy men and women between the ages of 20 to 49 years old.

Exclusion Criteria:

• A medical condition that places them at high risk for complications from influenza, including those with chronic heart or lung disease, such as asthma or reactive airway disease; people with medical conditions such as diabetes or kidney failure; or people with illnesses that weaken the immune system, or who take medications that can weaken the immune system.

• A history of Guillain-Barré Syndrome that occurred after receiving influenza vaccine

• Currently pregnant

• Have a severe allergy to chicken eggs or who are allergic to any of the nasal spray vaccine components

• Have had flu within the current flu season.

• Have had a flu vaccine within the current flu season.

• Have close contact with someone whose immune system is so weak they require care in a protected environment (such as bone marrow transplant unit).